SCHEMBL5950007

SCHEMBL5950007

O=C(Nc1cc(C(F)(F)F)cc(C(F)(F)F)c1)Nc1ccc(C(=O)N2CCCCC2)cc1-c1nnn[nH]1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 4/20 0.42
MEN1 O00255 1/20 0.42
TSHR P16473 1/20 0.42
KMT2A Q03164 1/20 0.42
POLB P06746 2/20 0.42
LMNA P02545 1/20 0.42
MAPT P10636 2/20 0.41
RHOC P08134 1/20 0.41
RHOA P61586 1/20 0.41
KDM1A O60341 1/20 0.41
EPHX2 P34913 5/20 0.40
ALDH1A1 P00352 2/20 0.40
KDM4E B2RXH2 1/20 0.40
HSD17B10 Q99714 1/20 0.40
MAPK10 P53779 1/20 0.39
PDK1 Q15118 2/20 0.39
PDK2 Q15119 2/20 0.39
PDK3 Q15120 2/20 0.39
PDK4 Q16654 2/20 0.39
MLYCD O95822 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5950152 0.93 RHOC (0.42) HPGDMEN1TSHRKMT2APOLB
SCHEMBL5950126 0.88 MAPT (0.43) HPGDTSHRPOLBMAPTEPHX2
SCHEMBL5950379 0.86 MAPT (0.50) HPGDTSHRPOLBLMNAMAPT
SCHEMBL5950251 0.85 SMN1; SMN2 (0.49) HPGDTSHRMAPTALDH1A1PDK1
SCHEMBL5950578 0.83 MAPT (0.48) HPGDLMNAMAPTALDH1A1KDM4E
SCHEMBL5950292 0.81 MAPT (0.43) HPGDMAPTEPHX2ALDH1A1KDM4E
SCHEMBL6188567 0.81 ALDH1A1 (0.44) HPGDKMT2APOLBMAPTALDH1A1
Emidurdar SCHEMBL1463101 0.80 KCNMA1 (0.54) LMNAMAPTALDH1A1NPC1RAB9A
SCHEMBL1463472 0.80 GRIK1 (0.47) MEN1KMT2AMAPT
Emidurdar SCHEMBL30845296 0.80 KCNMA1 (0.54) LMNAMAPTALDH1A1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060160856-A1 Diarylurea derivatives and their use as chloride channel blockers NEUROSEARCH A/S (DK) 2006-07-20 US claimed
JP-2005538152-A 2005-12-15 JP claimed
EP-1537075-A2 DIARYLUREA DERIVATIVES AND THEIR USE AS CHLORIDE CHANNEL BLOCKERS NEUROSEARCH A/S (DK) 2005-06-08 EP claimed
WO-2004022529-A2 DIARYLUREA DERIVATIVES AND THEIR USE AS CHLORIDE CHANNEL BLOCKERS NEUROSEARCH A/S (DK) 2004-03-18 WO claimed
US-20060160856-A1 Diarylurea derivatives and their use as chloride channel blockers NEUROSEARCH A/S (DK) 2006-07-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160856-A1 Diarylurea derivatives and their use as chloride channel blockers KIT, ORAI1, CACNA1C HPGD 1108/4885MEN1 1915/4885TSHR 4363/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.